For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Over the past four years, private equity (PE) firms that invested in life science assets have faced a difficult reality.

Canaccord analyst William Plovanic raised the firm’s price target on TriSalus Life Sciences (TLSI) to $12 from $11 and keeps a Buy rating on the ...

Texas’s premier life science conference returns to Houston in November, spotlighting breakthrough innovations in therapeutics, medical technology, and digital health. HOUSTON--(BUSINESS WIRE)--Rice ...

The real estate investment trust has been dealing with challenges in the life-sciences market, and its strategy includes ...

The developer behind Philadelphia's largest life sciences building says the market needs patience after venture capital ...

Humans have it. So does Drosophila. But not yeast. That "it" is a small pause at the start of gene activity—a brief molecular halt that may have helped life evolve from simple cells to complex animals ...